Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAmsterdam UMC, location VUmc
About this trial
COPPER is an international, multicenter, parallel-arm, phase III randomized controlled trial comparing two local treatment strategies (SABR or metastasectomy) for patients with an indication for local treatment for limited (max. three) colorectal pulmonary metastases
Eligibility criteria
Qualifiers
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG)-Performance status 0 - 2
Willing to provide informed consent
Patients with 1 to 3 lung metastases from colorectal cancer eligible for both a minimally invasive surgical resection and SABR, as assessed by the multidisciplinary tumor board (MDT)
Disqualifiers
Previous or present metastases outside liver or lungs
Concurrent malignant cancer, or history of other malignant cancers within the past 5 years (excluding prespecified low-risk cancers)
Hilar or mediastinal lymph node metastases
Poor cardiopulmonary function test
Trial design
Treatments tested in this trial
- Minimally invasive pulmonary metastasectomy
- Stereotactic ablative radiotherapy
Treatment groups
394 Participants
are divided into 2 treatment groupsSponsors and collaborators
Amsterdam UMC, location VUmc
Lead sponsor
Dutch Cancer Society
Collaborator
Source ClinicalTrials.gov